Assembling the brief…
The front page of AI-driven biology.
Topic
Standards, governance, validation expectations, and public policy affecting AI-enabled life-science work.
News
Policy & regulation
The FDA approved once-daily Rasonque, or daraxonrasib, for adults with metastatic pancreatic adenocarcinoma after prior systemic therapy or when multiagent therapy is not an option.
Company news
Capital and public listings improved in early 2026, but employment data still reflects the industry's recent contraction.
Policy & regulation
The agency moved deramiocel's decision date to November 22 while it reviews new follow-up data and analyses.
Company news
The FcRn blocker becomes the first FDA-approved treatment specifically for adults and adolescents with warm autoimmune hemolytic anemia.
Policy & regulation
The agency is asking how medical software that generates content or actions should be assessed for risk, tested before launch, and monitored afterward.
Clinical
Amylyx reports fewer severe hypoglycemic events with avexitide, while complete arm-level and registry-posted results remain unavailable.
Policy & regulation
A Joint Research Centre report calls for realistic capability claims, transparent reporting, and reproducible validation of biology AI systems.
Research
Karoline Kallis and colleagues report that an EHR model performed similarly across five health systems but much less sensitively in patients with sparse documentation.
Yijun Ren and colleagues report that a cross-jurisdiction analysis finds longer second-authorization delays when radiology AI reaches Europe before the United States.
Liron Leibovitch and colleagues report that a four-week emergency-department evaluation found mostly appropriate sampled outputs but falling clinician adoption and no reduction in length of stay.
Products & tools
No related releases yet.
Capital & partnerships
public market financing
Clinical development, regulatory activities, working capital, and general corporate purposes